BRCA1 and breast carcinoma: In addition, Wu et al. found that ALKBH5 removed the m6A modification of BRCA1 (DNA repair protein), stabilized BRCA1 mRNA and further enhanced DNA repair capacity, which results in reduced efficacy of doxorubicin in breast cancer.